Table 1 The characteristics of the included literature
First Author | Year | Country | Number of patients | Age | Therapeutic Drug | Study Designs | Literature Quality | Evaluation Indicators |
|---|---|---|---|---|---|---|---|---|
K. E. Wilson [10] | 2006 | United Kingdom | 35 | 5–10(years) | Midazolam Nitrous Oxide | Randomized controlled trial | HQ | Sedation and Analgesia Success Rate Adverse Effects Rate |
K. E. Wilson [11] | 2002 | United Kingdom | 44 | 10–16 (years) | Midazolam Nitrous Oxide | Randomized controlled trial | HQ | Sedation and Analgesia Success Rate Adverse Effects Rate |
K. E. Wilson [12] | 2002 | United Kingdom | 26 | 10–16 (years) | Midazolam Nitrous Oxide | Randomized controlled trial | HQ | Sedation and Analgesia Success Rate Adverse Effects Rate |
Tian Xiaohua [13] | 2015 | China | 67 | 4–14 (years) | Midazolam Nitrous Oxide | The cohort study | HQ | Sedation and Analgesia Success Rate Adverse Effects Rate |
Shi Xiangjun [14] | 2005 | China | 17 | 2–30 (years) | Midazolam | The cohort study | HQ | Sedation and Analgesia Success Rate Adverse Effects Rate |
Ma Lin [15] | 2012 | China | 46 | 26–84 (months) | Midazolam | The cohort study | HQ | Sedation and Analgesia Success Rate Adverse Effects Rate |
Nie Juan [16] | 2021 | China | 45 | 3–12 (years) | Midazolam | Randomized controlled trial | HQ | Sedation and Analgesia Success Rate Adverse Effects Rate |
Liu Jing [17] | 2020 | China | 57 | 6–8 (years) | Nitrous Oxide | Randomized controlled trial | HQ | Sedation and Analgesia Success Rate Adverse Effects Rate |